However, medications to lower plasma glucose and improve insulin resistance (including metformin and dapagliflozin) in adults with overweight/obesity and prediabetes did not decrease fasting plasma LEAP2 over 13 weeks [67]. Here, LEAP2 is linked to obesity disorder.